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PREVIOUTS studies (Marks and Bishop, 1957 Benjamin, 1960 anid Boyd,
(lapp and Finnegan, 1962) have shown that there is a decrease in glucose toleranice
in a variety of malignant diseases. In one study (Boyd et al., 1962) glucose
tolerance was improved after oestrogens had been given for breast or prostatic
carcinoma, and this was accompanied by clinical evidence ofregression ofthemalig-
nant disease. It was acknowledged that this phenomenon might be due merely
to the effects of oestrogens and be unrelated to the regression of tumour.
This paper is concerned with ain attempt to show a relationship between
abnormal glucose tolerance in cancer of various types and methods of treatment
other than the administration of oestrogens.
M1ATERIAL AND METHODS
In all of the patients studied the diagnosis of caincer had been confirmed
histologically. Twenty-nine patients were tested. Nine patients received
Ino specific treatment because the tumour was inoperable or because, in the
circumstances, other forms of treatment were considered inappropriate. A
further seven patients were treated, but for a variety ofreasons a second test could
not be carried out (some of the patients died soon after surgical operation, and
others were not well eniough to make the journey to the hospital out-patient
department).
The thirteen remaining patients were tested at intervals varying from one to
three months after the first test and at a time when they were considered to have
improved clinically as a result of treatment. Details of diagnosis and treatment
in the individual cases are giveii in Table I.
All patients were taking a normal diet but oni the day of the test were fasting
and at rest. None of them had clinical evidence of endocrine, renal or hepatic
disease. The test was performed in the manner previously described (Boyd
et al., 1962) and the result expressed as the glucose iincrement index (I.I.) as
suggested by Amatuzio et al. (1953). Blood glucose levels were again determined
by enzymatic methods as " true glucose " (Keilin and Hartree, 1945).
RESULTS
The findings are summarised in Table I and Fig. 1. The range of values for
the I.I. in normal people varies in different series. Duncan (1956), reported
3*15-4-62; Marks and Bishop (1957), 2-78-7 96 and Boyd et al. (1962), 2 52-D. H. A. BOYD AND MARGARET J. FLETCHER
TABLE I.-Glucose Increment Index for Malignant Disease Before and After
Treatment
Diagnosis
Bronchial carcinoma
,. 5..
Gastric carcinoma
Adenocarcinoma of colon
Rectal carcinoma
Hodgkin's disease
Polycythaemia vera
12 26 F Reticulum cell sarcoma
13 49 F Ovarian carcinoma
Glucose increment
index
Before After
Treatment treatment treatment
Radiotherapy 1- 75 2- 31
1- 82 1-06
2-38 2-38
Radiotherapy + 2 - 84 2- 34
Nitrogen mustard
Surgical resection 2- 1 1-87
2-16 2-77
1-93 2-23
1-17 1-06
2-13 1-63
Nitrogen mustard 1- 98 2 - 66
Radioactive phos- 1-39 1-92
phorus
Nitrogen mustard 1P98 1- 77
Radiotherapy 3 08 4-95
Mean 2-06 2 23
S.D. ±0 52 +0 96
Range 1-17-3-08 1- 06-4- 95
Analy8is of Significance
Cancer (untreated) v Cancer (treated) t = 0 27.
5- 13. Using the last figures, two patients in the present series had normal values
before treatment and three after treatment. The range of I.I. before treatment
was 1 17-3*08 with a mean of 2
- 06 (S.D. ± 0 52) and after treatment was 1 06-
4-95 with a mean of 2 23 (S.D. ± 0 96). Analysis of pre-treatment and post-
treatment figures show no statistical difference (t _ 0 27). Although the numbers
are small there is no obvious trend when individual types of malignant disease
and forms of treatment are considered.
DISCUSSION
Unlike the oestrogen treatment of prostatic and mammary carcinoma, the
treatment of other forms of malignant disease by surgical resection, radiotherapy
and cytotoxic drugs does not appear to result in improvement in glucose tolerance.
This may help to support the suggestion made by Boyd et al. (1962), that the
improvement seen in patients with prostatic and mammary carcinoma is due
merely to oestrogen effect and not to any associated changes in the malignant
disease.
This study may also help to underline the fact that abnormal glucose tolerance
is not a constant feature of malignant disease, that it cannot be related to the
success or failure of treatment, and that tests to detect it are unreliable as
diagnostic measures for malignant disease.
SUMMARY
The results are presented of intravenous glucose tolerance tests performed on
13 patients with a variety of malignant diseases before and after several forms of
treatment.
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FIG. 1.-Comparison of glucose increment index in malignant disease before and after treatment.
The difference is not statistically significant; and this suggests that in malig-
nant disease, treatment has no effect on glucose tolerance.
We wish to thank Prof. S. Alstead for helpful criticism of this paper and Mr.
M. Davis for statistical advice.
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